Back to Journals » Drug Design, Development and Therapy » Volume 4
Original Research

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
18,899 | Dovepress* | 17,078+ | 2,068 | 19,146 | |
PubMed Central* | 1,821 | 670 | 2,491 | ||
Totals | 18,899 | 2,738 | 21,637 | ||
*Since 15 November 2010 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
8 | 0 | 0 | 0 | 0 | 8 |
View citations on PubMed Central and Google Scholar